



Wyeth Pharmaceuticals
Huntercombe Lane South
Taplow, Maidenhead
Berkshire, SL6 0PH
Tel: +44 (0)1628 604377
Fax: +44 (0)1628 666368

NEWS RELEASE

04 July 2007

WYETH WINS WORLD AWARD FOR INVESTMENT IN SCOTLAND

Translational Medicine Research Collaboration Scoops 'Best Investment in Europe' Award at La Baule

Wyeth Pharmaceuticals, a division of Wyeth, one of the world's largest pharmaceutical companies, was today awarded one of three 'Best Investment in Europe' titles at the La Baule World Investment Conference for its leading role in creating the world's first Translational Medicine Research Collaboration (TMRC) in Scotland in 2006.

The award was made at the event in France in recognition of Wyeth's large financial investment, its determination to make the project succeed and for the number of highly skilled jobs created, projected at upwards of 120 jobs over five years in Scotland.

Wyeth Pharmaceuticals, with headquarters in Collegeville, Pennsylvania, plans to invest an estimated £33m in the collaboration in its first five years with an option to extend for a further five years. Scottish Enterprise will invest up to £17.5m.

Frank Walsh Ph.D., Executive Vice President of Wyeth Research said; "Wyeth is tremendously honoured to receive this award. We believe this is a truly novel and innovative collaboration and we are proud that it is being recognized as such. Scotland offers enormous potential in the field of life sciences and in particular translational medicine. It is the hope of all partners in this collaboration that the research performed will have direct consequences on patient health through the speedy and safe development of novel therapeutics."

The £50 million collaboration comprises four of Scotland's leading universities (Aberdeen, Dundee, Edinburgh and Glasgow), Wyeth Pharmaceuticals, Scottish Enterprise and NHS Scotland Grampian, Greater Glasgow, Lothian and Tayside, and will provide new impetus for Scotland to lead the world in the development of personalised medicine,



John Wyeth & Brother Limited
Registered in England No. 135937
Registered Office: Huntercombe Lane South
Taplow, Maidenhead, Berkshire, SL6 0PH

Incorporating: SMA Nutrition

ZGEN377
Date of preparation: June 2007

bringing new treatments to patients suffering from a range of serious illnesses.

TMRC has already invested almost £8 million of funding to support 28 new research projects covering a wide range of therapeutic areas including cardiovascular and metabolic disease, the central nervous system, oncology, inflammation, and women's health.

As a result, over 40 new jobs have already been created with a further 50 projected for the Core Laboratory which is located in Dundee.

Martin Togneri, Chief Executive of Scottish Development International, who is at La Baule, said: "With over three and a half thousand recorded inward investment projects taking place in Europe in 2006, to win this award is a great achievement and testament to everyone concerned in the delivery of this world first in Scotland.

Wyeth's investment is a tremendous endorsement of the country's excellence in life sciences, its culture of collaboration between the NHS and Universities, and the fantastic support that the project has been met with from everyone in Scotland. It is right that its efforts in creating the TMRC are recognised globally."

- Ends -

For further information, please contact:

Karen Tait, Corporate Affairs, Wyeth UK
Tel: 01628 685463
Fax:01628 414878
Email: taik1@wyeth.com

Stephen Sharp, Senior Media Relations Executive,
Scottish Enterprise
Tel: 0141 228 7364
Mob: 07786 126 629
Email: Stephen.sharp@scotent.co.uk

ZGEN377

Date of preparation: June2007

Notes to editors

About Wyeth Pharmaceutical

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, haemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

About Translational Medicine

Translational Medicine is a revolutionary new approach to developing new drugs and treatments by focusing research on new tests for the diagnosis and monitoring of human diseases. These tests, called biomarkers, are new proteins or markers that can be measured in blood samples or X-rays of patients. They can then be used to follow the progress and response to the treatment of patients with diseases such as heart attacks, cancer, depression and osteoporosis. This enables further development and enhancement of therapies for treating and preventing these diseases. www.tmrc.co.uk

More information on the other collaboration partners can be found on their web sites here:

Wyeth	www.wyeth.com
University of Aberdeen	www.abdn.ac.uk
University of Dundee	www.dundee.ac.uk
University of Edinburgh	www.ed.ac.uk
University of Glasgow	www.gla.ac.uk
NHS Greater Glasgow	www.nhs.gov.uk
NHS Grampian	www.nhs.gov.uk
NHS Lothian	www.show.scot.nhs.uk
NHS Tayside	www.nhs.gov.uk
Scottish Enterprise	www.scottish-enterprise.com
Scottish Development International	www.scottishdevelopmentinternational.com

ZGEN377

Date of preparation: June2007